Investor Presentation First Nine Months of 2022
57
Investor presentation
First nine months of 2022
Phase 3 trial programme, COMBINE, has been initiated with
IcoSema
IcoSema characteristics
IcoSema is a fixed dose combination
of insulin icodec and semaglutide
• Simple and convenient once-weekly
injection
کی
COMBINE 1
Post-basal insulin
Focused phase 3 trial programme
•
•
•
Initiated in Q2 2022
1290 patients* previously on basal-insulin
52-week vs. insulin icodec
•
Prim. endpoint: HbA₁, superiority
•
Sec. endpoint: Weight and hypo superiority
COMBINE 2
Post-GLP-1
•
Phase 3a programme with IcoSema
Aims to confirm efficacy and safety
across three global trials
Expected completion during 2024
COMBINE 3
Basal insulin
intensification
*Patients with Type 2 Diabetes Mellitus
•
•
Initiated in Q2 2022
680 patients* previously on GLP-1 RA
52-week vs. semaglutide 1.0mg
Primary endpoint: HbA1c superiority
.
Initiated in Q4 2021
• 680 patients* previously on basal insulin
52-week vs. insulin glargine + insulin aspart
•
•
•
Prim. endpoint: HbA₁ non-inferiority
Sec. endpoint: Weight and hypo superiority
2021
2022
2023
2024
Novo NordiskⓇView entire presentation